Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

It has previously been observed that a loss of β-catenin expression occurs with melanoma progression and that nuclear β-catenin levels are inversely proportional to cellular proliferation, suggesting that activation of the Wnt/β-catenin pathway may provide benefit for melanoma patients. In order to...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkinson, Jennifer M., Rank, Kenneth B., Zeng, Yi, Capen, Andrew, Yadav, Vipin, Manro, Jason R., Engler, Thomas A., Chedid, Marcio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411090/
https://www.ncbi.nlm.nih.gov/pubmed/25915038
http://dx.doi.org/10.1371/journal.pone.0125028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411090/
https://www.ncbi.nlm.nih.gov/pubmed/25915038
http://dx.doi.org/10.1371/journal.pone.0125028

Ejemplares similares